{"sentence": "Human pharmacologic studies have shown that <e1> Ritalin </e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and <e2> tricyclic drugs </e2> (imipramine, clomipramine, desipramine).", "relation": "1", "e1": "Ritalin", "e2": "tricyclic drugs", "evs": ""}
{"sentence": "However, the co administration of <e1> SPIRIVA </e1> with other <e2> anticholinergic </e2> containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.", "relation": "0", "e1": "SPIRIVA", "e2": "anticholinergic", "evs": ""}
{"sentence": "No significant adverse interactions with common premedications (such as atropine, <e1> scopolamine </e1> , glycopyrrolate, <e2> diazepam </e2> , hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.", "relation": "0", "e1": "scopolamine", "e2": "diazepam", "evs": ""}
{"sentence": "Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations.", "relation": "1", "e1": "SUTENT", "e2": "saquinavir", "evs": ""}
{"sentence": "<e1> morphine </e1> , theophylline, <e2> aminophylline </e2> , succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.", "relation": "0", "e1": "morphine", "e2": "aminophylline", "evs": ""}
{"sentence": "The concomitant use of other CNS depressants including sedatives, <e1> hypnotics </e1> , tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2> alcohol </e2> may produce additive CNS depressant effects.", "relation": "0", "e1": "hypnotics", "e2": "alcohol", "evs": ""}
{"sentence": "However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and <e1> tramadol </e1> has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by <e2> ondansetron </e2> .", "relation": "0", "e1": "tramadol", "e2": "ondansetron", "evs": ""}
{"sentence": "Human pharmacologic studies have shown that <e1> Ritalin </e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, <e2> clomipramine </e2> , desipramine).", "relation": "1", "e1": "Ritalin", "e2": "clomipramine", "evs": ""}
{"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.", "relation": "0", "e1": "antihistamines", "e2": "phenothiazines", "evs": ""}
{"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.", "relation": "0", "e1": "desmethyldiazepam", "e2": "nifedipine", "evs": ""}
{"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e1> miconazole </e1> ) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily.", "relation": "0", "e1": "miconazole", "e2": "vinblastine", "evs": ""}
{"sentence": "<e1> Sulfonamides </e1> can also displace <e2> methotrexate </e2> from plasma protein-binding sites, thus increasing free methotrexate concentrations.", "relation": "1", "e1": "Sulfonamides", "e2": "methotrexate", "evs": ""}
{"sentence": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . <e1> Nonsteroidal anti-inflammatory agents </e1> , including <e2> FELDENE </e2> , have been reported to increase steady state plasma lithium levels.", "relation": "0", "e1": "Nonsteroidal anti-inflammatory agents", "e2": "FELDENE", "evs": ""}
{"sentence": "<e1> Mephenytoin </e1> may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, <e2> furosemide </e2> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.", "relation": "1", "e1": "Mephenytoin", "e2": "furosemide", "evs": ""}
{"sentence": "Concomitant administration of <e1> TRENTAL </e1> and <e2> theophylline </e2> -containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.", "relation": "1", "e1": "TRENTAL", "e2": "theophylline", "evs": ""}
{"sentence": "<e1> Pindolol </e1> has been shown to increase serum <e2> thioridazine </e2> levels when both drugs are co-administered.", "relation": "1", "e1": "Pindolol", "e2": "thioridazine", "evs": ""}
{"sentence": "Drugs such as erythromycin, diltiazem, verapamil, <e1> ketoconazole </e1> , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2> midazolam </e2> .", "relation": "1", "e1": "ketoconazole", "e2": "midazolam", "evs": ""}
{"sentence": "<e1> Sulfonamides </e1> : Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the <e2> sulfonamide </e2> .", "relation": "0", "e1": "Sulfonamides", "e2": "sulfonamide", "evs": ""}
{"sentence": "Another study at a 400-mg and 800-mg daily dose of <e1> fluconazole </e1> demonstrated that <e2> DIFLUCAN </e2> taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.", "relation": "0", "e1": "fluconazole", "e2": "DIFLUCAN", "evs": ""}
{"sentence": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1> Sanctura </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, <e2> vancomycin </e2> , metformin and tenofovir).", "relation": "1", "e1": "Sanctura", "e2": "vancomycin", "evs": ""}
{"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e1> naproxen </e1> , <e2> warfarin </e2> , methotrexate, and possibly corticosteroids.", "relation": "0", "e1": "naproxen", "e2": "warfarin", "evs": ""}
{"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1> indinavir </e1> , nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.", "relation": "0", "e1": "indinavir", "e2": "ritonavir", "evs": ""}
{"sentence": "Beta adrenergic agonists should be administered with caution to patients being treated with <e1> monoamine oxidase inhibitors </e1> or tricyclic antidepressants, since the action of <e2> beta adrenergic agonists </e2> on the vascular system may be potentiated.", "relation": "0", "e1": "monoamine oxidase inhibitors", "e2": "beta adrenergic agonists", "evs": ""}
{"sentence": "Coadministration with <e1> acetaminophen </e1> reduced the peak concentration and AUC values for <e2> rimantadine </e2> by approximately 11%.", "relation": "1", "e1": "acetaminophen", "e2": "rimantadine", "evs": ""}
{"sentence": "Anticoagulants (such as <e1> heparin </e1> and <e2> vitamin K antagonists </e2> ) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.", "relation": "0", "e1": "heparin", "e2": "vitamin K antagonists", "evs": ""}
{"sentence": "Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and <e1> rifampicin </e1> ), the clearance of <e2> ondansetron </e2> was significantly increased and ondansetron blood concentrations were decreased.", "relation": "1", "e1": "rifampicin", "e2": "ondansetron", "evs": ""}
{"sentence": "The concomitant use of other CNS depressants including sedatives, <e1> hypnotics </e1> , tranquilizers, general anesthetics, <e2> phenothiazines </e2> , other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.", "relation": "0", "e1": "hypnotics", "e2": "phenothiazines", "evs": ""}
{"sentence": "<e1> Sulfoxone </e1> may increase the effects of barbiturates, <e2> tolbutamide </e2> , and uricosurics.", "relation": "1", "e1": "Sulfoxone", "e2": "tolbutamide", "evs": ""}
{"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), <e2> antihistamines </e2> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.", "relation": "0", "e1": "antiarrhythmic agents of class I", "e2": "antihistamines", "evs": ""}
{"sentence": "<e1> Warfarin </e1> : A multidose study of <e2> oxandrolone </e2> , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.", "relation": "0", "e1": "Warfarin", "e2": "oxandrolone", "evs": ""}
{"sentence": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2> MIRAPEX </e2> .", "relation": "1", "e1": "phenothiazines", "e2": "MIRAPEX", "evs": ""}
{"sentence": "Human pharmacologic studies have shown that <e1> Ritalin </e1> may inhibit the metabolism of coumarin anticoagulants, <e2> anticonvulsants </e2> (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).", "relation": "1", "e1": "Ritalin", "e2": "anticonvulsants", "evs": ""}
{"sentence": "Sympathomimetics: <e1> Metolazone </e1> may decrease arterial responsiveness to <e2> norepinephrine </e2> , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.", "relation": "1", "e1": "Metolazone", "e2": "norepinephrine", "evs": ""}
{"sentence": "However, in a drug-drug interaction study, mean <e1> levonorgesterol </e1> AUC was decreased by 15% when coadministered with <e2> mycophenolate mofetil </e2> .", "relation": "1", "e1": "levonorgesterol", "e2": "mycophenolate mofetil", "evs": ""}
{"sentence": "One case of hypertensive crisis has been reported in a patient taking the recommended doses of <e1> selegiline </e1> and a sympathomimetic medication ( <e2> ephedrine </e2> ).", "relation": "1", "e1": "selegiline", "e2": "ephedrine", "evs": ""}
{"sentence": "Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as <e1> alcohol </e1> , sedatives, antihistaminics, or <e2> psychotropic drugs </e2> .", "relation": "0", "e1": "alcohol", "e2": "psychotropic drugs", "evs": ""}
{"sentence": "MAO inhibitors and <e1> beta adrenergic blockers </e1> increase the effects of <e2> pseudoephedrine </e2> .", "relation": "1", "e1": "beta adrenergic blockers", "e2": "pseudoephedrine", "evs": ""}
{"sentence": "However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that <e1> ondansetron </e1> may be associated with an increase in patient controlled administration of <e2> tramadol </e2> .4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.", "relation": "1", "e1": "ondansetron", "e2": "tramadol", "evs": ""}
{"sentence": "Coadministration of methyldopa with <e1> ferrous sulfate </e1> or <e2> ferrous gluconate </e2> is not recommended.", "relation": "0", "e1": "ferrous sulfate", "e2": "ferrous gluconate", "evs": ""}
{"sentence": "<e1> Pantoprazole </e1> has a much weaker effect on <e2> clopidogrel </e2> 's pharmacokinetics and on platelet reactivity during concomitant use.", "relation": "1", "e1": "Pantoprazole", "e2": "clopidogrel", "evs": ""}
